Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB) are neurodegenerative disorders characterized by the accumulation of &#
x3b1;-synuclein aggregates. &#
x3b1;-synuclein forms droplets via liquid-liquid phase separation (LLPS), followed by liquid-solid phase separation (LSPS) to form amyloids, how this process is physiologically-regulated remains unclear. &#
x3b2;-synuclein colocalizes with &#
x3b1;-synuclein in presynaptic terminals. Here, we report that &#
x3b2;-synuclein partitions into &#
x3b1;-synuclein condensates promotes the LLPS, and slows down LSPS of &#
x3b1;-synuclein, while disease-associated &#
x3b2;-synuclein mutations lose these capacities. Exogenous &#
x3b2;-synuclein improves the movement defects and prolongs the lifespan of an &#
x3b1;-synuclein-expressing NL5901 Caenorhabditis elegans strain, while disease-associated &#
x3b2;-synuclein mutants aggravate the symptoms. Decapeptides targeted at the &#
x3b1;-/&#
x3b2;-synuclein interaction sites are rationally designed, which suppress the LSPS of &#
x3b1;-synuclein, rescue the movement defects, and prolong the lifespan of C. elegans NL5901. Together, we unveil a Yin-Yang balance between &#
x3b1;- and &#
x3b2;-synuclein underlying the normal and disease states of PD and DLB with therapeutical potentials.